|
| 37743097 | Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias. | Br J Haematol | 2024 |
| 37480164 | Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms. | Pediatr Blood Cancer | 2023 |
| 36250964 | Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma. | Pediatr Blood Cancer | 2023 |
| 36037430 | Chronic conditions, late mortality, and health status after childhood AML: a Childhood Cancer Survivor Study report. | Blood | 2023 |
| 36332007 | Hypodiploidy has unfavorable impact on survival in pediatric acute myeloid leukemia: an I-BFM Study Group collaboration. | Blood advances | 2023 |
| 35987350 | Aberrant T-cell exhaustion in severe combined immunodeficiency survivors with poor T-cell reconstitution after transplantation. | J Allergy Clin Immunol | 2023 |
| 37415296 | Comparison of variants in TPMT and NUDT15 between sequencing and genotyping methods in a multistate pediatric institution. | | 2023 |
| 37287368 | Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. | Proteomics Clin Appl | 2023 |
| 37267439 | Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. | Blood Adv | 2023 |
| 36815378 | Comprehensive molecular and clinical characterization of <i>NUP98</i> fusions in pediatric acute myeloid leukemia. | Haematologica | 2023 |
| 37455243 | Position paper: The time for cooperative group study of ropeginterferon alfa-2b in young patients with myeloproliferative neoplasms is now. | Pediatr Blood Cancer | 2023 |
| 36634304 | CREBBP alterations are associated with a poor prognosis in de novo AML. | Blood | 2023 |
| 37250111 | Machine learning classifier approaches for predicting response to RTK-type-III inhibitors demonstrate high accuracy using transcriptomic signatures and <i>ex vivo</i> data. | Bioinform Adv | 2023 |
| 36689724 | SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia. | Blood Adv | 2023 |
| 37370721 | Bone Marrow Microenvironment-Induced Chemoprotection in Rearranged Pediatric AML Is Overcome by Azacitidine-Panobinostat Combination. | | 2023 |
| 36795987 | Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. | J Clin Oncol | 2023 |
| 36669140 | Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. | J Clin Oncol | 2023 |
| 34472213 | Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group. | Pediatr Blood Cancer | 2022 |
| 35657346 | Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium. | Mol Cancer Ther | 2022 |
| 36123353 | Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. | Nat Commun | 2022 |
| 35407531 | Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts. | Journal of Clinical Medicine | 2022 |
| 35717004 | Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy. | Transplant Cell Ther | 2022 |
| 33375775 | Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. | Haematologica | 2022 |
| 34990262 | Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. | J Clin Oncol | 2022 |
| 35312779 | Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma. | Mol Cancer Ther | 2022 |
| 34918996 | Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML. | Pediatric Hematology and Oncology | 2022 |
| 35268423 | Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia. | Journal of Clinical Medicine | 2022 |
| 34855461 | CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. | J Clin Oncol | 2022 |
| 35203280 | Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of and Mutations in Induced Pluripotent Stem Cells with Trisomy 21. | Cells | 2022 |
| 35021602 | Clinical relevance of proteomic profiling in <i>de novo</i> pediatric acute myeloid leukemia: a Children's Oncology Group study. | Haematologica | 2022 |
| 35158884 | Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival. | Cancers (Basel) | 2022 |
| 34762093 | Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial. | JAMA Oncol | 2022 |
| 35326701 | Mesothelin: An Immunotherapeutic Target beyond Solid Tumors. | Cancers | 2022 |
| 35121370 | Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma. | Eur J Cancer | 2022 |
| 34582559 | The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. | Blood | 2022 |
| 34369483 | A 3-D hydrogel based system for hematopoietic differentiation and its use in modeling down syndrome associated transient myeloproliferative disorder. | Biomaterials Science | 2021 |
| 33694257 | Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia. | Pediatr Blood Cancer | 2021 |
| 34066095 | Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. | Cancers (Basel) | 2021 |
| 33951732 | CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group. | Blood | 2021 |
| 34048275 | Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric <i>KMT2A</i>-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531. | J Clin Oncol | 2021 |
| 33672815 | Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group. | Cancers (Basel) | 2021 |
| 33619171 | The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. | Clin Cancer Res | 2021 |
| 33938941 | Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia. | Blood Adv | 2021 |
| 34320162 | High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. | Blood | 2021 |
| 33298592 | ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium. | Mol Cancer Ther | 2021 |
| 32804009 | Initial <i>in vivo</i> testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium. | Pediatr Hematol Oncol | 2021 |
| 32959058 | Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report. | Blood | 2021 |
| 32554562 | Comparison of total body irradiation non-total body irradiation containing regimens for de novo acute myeloid leukemia in children. | Haematologica | 2021 |
| 34662145 | Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research. | JCO Clin Cancer Inform | 2021 |
| 34547772 | CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. | Blood Adv | 2021 |